Akero Therapeutics (AKRO) Projected to Post Quarterly Earnings on Friday

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Friday, May 9th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). On average, analysts expect Akero Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Akero Therapeutics Trading Down 0.7 %

Shares of AKRO stock opened at $45.31 on Friday. Akero Therapeutics has a 1 year low of $17.86 and a 1 year high of $58.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The stock's 50 day simple moving average is $41.71 and its two-hundred day simple moving average is $36.93. The company has a market cap of $3.61 billion, a PE ratio of -12.08 and a beta of -0.18.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AKRO. HC Wainwright upped their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. Bank of America raised Akero Therapeutics from a "neutral" rating to a "buy" rating and upped their target price for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Canaccord Genuity Group upped their target price on Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Finally, Citigroup upped their target price on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $76.29.

Insider Buying and Selling at Akero Therapeutics

In related news, COO Jonathan Young sold 10,000 shares of Akero Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $53.81, for a total value of $538,100.00. Following the completion of the sale, the chief operating officer now directly owns 251,147 shares in the company, valued at $13,514,220.07. The trade was a 3.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Patrick Lamy sold 1,000 shares of Akero Therapeutics stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $48.09, for a total value of $48,090.00. Following the completion of the sale, the vice president now owns 33,492 shares of the company's stock, valued at $1,610,630.28. The trade was a 2.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 227,458 shares of company stock valued at $10,271,361 in the last ninety days. Corporate insiders own 7.94% of the company's stock.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.